Press review

 - 

Polish medicines official arrested on corruption charges

Country : Poland, Russia

Keywords :
WARSAW, 14 Aug (APM) - The president of the commission on medicinal products working with the Polish Office for the Registration of Medicinal Products (URPL) has been arrested on corruption charges related to the launch of medical cannabis onto the Polish market, reported Dziennik Gazeta Prawna (pA1, pA7) on Monday.
According to the Central Anti-Corruption Bureau (CBA), he promised to market medicinal marijuana in exchange for a bribe, said the paper.
It added that if the allegations of the CBA are confirmed, a review will be made of all the activities of the chairman taken in recent years.
This could mean authorities will check hundreds of proceedings in which the commission assessed whether a given drug should be available in Poland.

First Covid-19 vaccine authorised in Russia

Russian President Vladimir Putin has announced the approval of the world’s first Covid-19 vaccine despite concerns from scientists that the vaccine has not been tested in Phase III trials, reported Rzeczpospolita (pA7) on Wednesday and (pA16) on Friday, and Parkiet Gazeta Gieldy (p9) on Friday.
Putin claims the vaccine, known as Sputnik V, it has already been administered to one of his daughters.

Polish biotech share prices started stabilising

Shares in biotechs in Poland, which have recorded rising prices for some months, have recorded the first declines this year.
Experts say this could mean the end of the stock exchange bubble and a review of core businesses, reported Parkiet Gazeta Gieldy (p1, p4, p7) on Saturday, and Rzeczpospolita (pA16) and Parkiet Gazeta Gieldy (p9) on Friday.
One company with a declining share price was Biomed Lublin, a Polish tuberculosis vaccine producer and one of the largest listed biotechs working on a Covid-19 immunoglobulin drug.
After plummeting by 25% on Friday morning last week, it ended the day with a 6% rise. Biomed’s current capitalisation is 1.5 billion zlotys (€339 million), 52 times higher than at the beginning of the year.
BioMaxima’s price has risen by 530% since March and its current capitalisation is 160 million zlotys (€36.26 million). Meanwhile, Neuca, Poland’s leading pharmaceutical wholesaler, which is focusing on expansion through clinical trial services and acquisitions on EU markets, is recording continuous rises in its share price, reported the newspapers on Saturday.
rw/tm

[TM2QF1WN7]

TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT

Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations

Events coverage with a unique focus on Market Access & sustainability of healthcare systems

6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris

Ask for a Free trial and get access to the latest stories

Our coverage includes:
  • Health Care
  • Market Access
  • HTA – policies & practices
  • European medicine regulations
  • Drug safety issues
  • Pricing & Reimbursement
  • International medicines agencies

If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.

REQUEST

an initial 10 day temporary access of APM Health Europe.